SpinQ and DIVBIO Add a Five-Qubit Circuit to GLP-1 Receptor Potency Prediction: What the arXiv Study of 9 October 2026 Shows

A five-qubit circuit sharpens GLP-1 receptor potency prediction

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

Researchers at the Shenzhen quantum computing company SpinQ Technology and the Shenzhen drug developer DIVBIO Pharmaceutical report that a small simulated quantum circuit, bolted onto a conventional neural network, makes slightly better predictions of how strongly candidate molecules switch on the GLP-1 receptor. That receptor is the target of the drug class now used widely for type 2 diabetes and weight management, so even modest gains in early compound triage attract attention.

The preprint, posted to arXiv on 9 October 2026 by Chenyan Jia, Yaping Ma, Yuen Wang and Cong Guo, tests what the authors call a quantum-circuit residual head: a five-qubit circuit that adds a correction on top of an ordinary linear prediction. Its subject is potency prediction, the task of estimating from a molecule's structure the concentration at which it produces half of its maximal effect in a laboratory assay. The study also includes a careful classical control, and that control shapes how the result should be read.

The full paper, its 19 pages of supporting information and the abstract are open on arXiv under identifier 2610.13037. It has not yet been peer reviewed.

The team drew its measurements from release 37 of ChEMBL, the open bioactivity database run by EMBL's European Bioinformatics Institute. They kept only records for the human receptor that measured cAMP, the signalling molecule a cell produces when the GLP-1 receptor is activated, and that reported an exact EC50 value. After removing flagged and duplicate entries and merging repeat measurements of the same structure by their median, the GLP-1 receptor set held 1,052 compounds, of which 472 were small molecules and 580 were peptides under the authors' grouping rule, which counts amide bonds.

Two further receptors served as checks. The beta-2 adrenergic receptor (ADRB2) set held 829 compounds, 711 of them small molecules, and the melanocortin-4 receptor (MC4R) set held 767. Both receptors are established drug targets, the first in asthma and the second in rare genetic forms of obesity.

The authors point out a limitation of public potency data. A single cAMP potency value merges measurements taken in different laboratories under different assay conditions, so part of the error any model shows reflects noise in the labels themselves.